Plus: Maternal GBS vaccine trial results published, breast cancer service targets missed in Wales, and parenthood's unequal health impact.
DKSH signed an agreement to acquire the low-dose oral contraceptive brand Meliane from Bayer, expanding its Healthcare Own Brands portfolio into women’s health. This transaction, involving a brand available for over 30 years across 30 markets, will close by the end of Q3 2026. Separately, a phase 1/2 study found the GBS6 vaccine to be safe and immunogenic, inducing antibody responses in infants whose parent was vaccinated while pregnant, with results published on 28 July 2026. The Welsh Government is urged to invest in breast cancer services after 60% of patients were seen within 62 days of initial referral, falling short of the 75% target. Five takes inside, plus a quick-hits roundup.
VIA FemTech Insider
DKSH signed an agreement to acquire the low-dose oral contraceptive brand Meliane from Bayer. This acquisition expands DKSH's Healthcare Own Brands portfolio into women’s health. The transaction, involving a brand available for over 30 years across 30 markets, will close by the end of Q3 2026. This move indicates continued M&A activity within the women's health pharmaceutical sector.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
60% of patients were seen within 62 days of initial referral in Wales, according to figures published July 23. This falls short of the 75% target, which Wales met only three times since 2020. Breast Cancer Now urges action, as 2,800 people are diagnosed with breast cancer annually, a number projected to rise 23% by 2035.
Read the full story →
— The Luteal Editorial Team
VIA Nature Medicine
A phase 1/2 study found the maternal hexavalent 6 polysaccharide-protein conjugate group B Streptococcus vaccine (GBS6) to be safe and immunogenic. The GBS6 vaccine induced antibody responses in infants whose parent was vaccinated while pregnant. The article published online on 28 July 2026.
Read the full story →
— The Luteal Editorial Team
VIA Kaiser Family Foundation Women's Health
An ongoing FDA re-review of mifepristone occurs while awareness of the abortion pill's safety and prevalence remains limited. Voters who prioritize abortion policy for 2026 midterm candidates are disproportionately Democrats. Femtech operators should note limited public awareness impacts education strategies.
Read the full story →
— The Luteal Editorial Team
VIA Sunfish
Sunfish has launched Sunfish Starts, a six-month digital program built for the stretch before treatment begins — when prospective parents know they want a child but not where to start, what it will cost, or how ready their bodies are. The program pairs discounted baseline diagnostics for women and men with cost estimates, insurance navigation, grant and fertility loan access, a personalized readiness dashboard, and stage-specific educational modules.
Read the full story →
— The Luteal Editorial Team